Catalyst Wire Dossier Catalyst Wire Dossier

Narlumosbart (JMT103)

Narlumosbart · Shanghai JMT-Bio Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Narlumosbart (JMT103), covering 2023-04-19 to 2023-04-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone [Phase 3]

See pricing